2.20
+0.04(+1.85%)
Currency In USD
Address
3800 Bridge Parkway
Redwood City, CA 94065
United States of America
Phone
650 453 0000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
134
First IPO Date
December 04, 2020
| Name | Title | Pay | Year Born |
| Dr. Omid C. Farokhzad M.D., Ph.D. | Founder, Chief Executive Officer, & Chair of the Board of Directors | 1.19M | 1969 |
| Mr. David R. Horn | President,Treasurer & Chief Financial Officer | 746,652 | 1968 |
| Kenny Ross | Chief Operations & Product Officer | 0 | N/A |
| Dr. Serafim Batzoglou Ph.D. | Chief Data Officer | 0 | N/A |
| Mr. Martin Goldberg Ph.D. | Senior Vice President of Product Development | 0 | N/A |
| Dr. Asim Siddiqui Ph.D. | Senior Vice President of Research & Tech Development | 0 | N/A |
| Ms. Marissa Dixon | Chief People Officer | 0 | N/A |
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.